Experience

Actinium Pharmaceuticals, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Financial Officer

  • Oct 2015 - Present

  Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors.



Protea Biosciences

• Morgantown, WV

• Vice President of Corporate Finance and Development

  • Sep 2012 - May 2015

  Protea is a leader in the field of mass spectrometry molecular imaging - the identification and localization of the molecular products of living cells, that is foundational science for all pharmaceutical, medical, and life science research. Protea is a leader in the field of mass spectrometry molecular imaging - the identification and localization of the molecular products of living cells, that is foundational science for all pharmaceutical, medical, and life science research.



Caliber Imaging & Diagnostics, Inc.

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Regional Manager

  • Jun 2010 - Jun 2012

  Based in New York in the USA, Caliber ID is a medical technologies company that designs, develops, and markets innovative imaging solutions that show tissue at the cellular level. Founded in 1991 and originally named Lucid Technologies, Caliber Imaging & Diagnostics, Inc. is currently the only company in the world to offer in vivo confocal microscopes designed specifically for imaging skin and other tissue. Caliber ID’s Rapid Cell ID technology enables scientists and physicians to characterize intact normal and abnormal cellular architecture that is otherwise invisible to the naked eye.



Forge Financial Group

• Financial Services
• 1 - 100 Employee

• Life Sciences Investment Banking

  • 2009 - Jul 2010



Jesup & Lamont

• Financial Services
• 1 - 100 Employee

• Assistant Vice President - Life Sciences Investment Banking

  • Feb 2008 - Aug 2009